Search Results
Your search for The matches 34642 pages
Showing 21751 - 21800
W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition
W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.
Sumanta K. Pal, MD, on RCC and Tumor Profiling
Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract 434)
Paul L. Nguyen, MD, on Predicting Metastasis and Mortality
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, discuses an evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic needle biopsy specimens. (Abstract 4)
Toni K. Choueiri, MD, on Untreated RCC: Phase II Trial Results
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on atezolizumab with or without bevacizumab vs sunitinib in patients with untreated metastatic renal cell carcinoma. (Abstract 431)
Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals
Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.
Emma Hall, PhD, on Bladder Cancer: Results From the BC2001 Trial
Emma Hall, PhD, of the Institute of Cancer Research, London, discusses long-term outcomes with chemoradiotherapy vs radiotherapy alone, and standard vs reduced high-dose volume radiotherapy in muscle-invasive bladder cancer. (Abstract 280)
L. Michael Glodé, MD, on Prostate Cancer: Results From SWOG S9921
L. Michael Glodé, MD, of the University of Colorado Cancer Center, discusses study findings on adjuvant androgen deprivation vs mitoxantrone plus prednisone plus ADT in high-risk prostate cancer patients following radical prostatectomy. (Abstract 2)
George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons
George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con” viewpoints for treatment intensification in patients with poor-prognosis germ cell tumors with unfavorable marker decline.
ASCO-SITC Clinical Immuno-Oncology Symposium: Utility of Biomarkers for Predicting Colorectal Cancer Survival Depends on Tumor Location
A large population-based study suggests that the utility of particular types of tumor-infiltrating lymphocytes (TILs) to predict colorectal cancer survival depends on where the tumor originates in the body. Although prior research has shown an association between high TIL density and longer...
ASCO-SITC Clinical Immuno-Oncology Symposium: Response to Cancer Immunotherapy May Depend on Gut Bacteria
Researchers have found a link between microbes in the gut (the microbiome) and response to immunotherapy. In the study, the ability of patients with advanced melanoma to respond to programmed cell death protein 1 (PD-1) immune checkpoint inhibitors depended on the presence of a diverse microbiome...
Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses a single-arm biomarker-based study of savolitinib in patients with advanced papillary renal cell cancer. (Abstract 436)
Charles G. Drake, MD, PhD, on Prostate Cancer and Immunology: Expert Perspective
Charles G. Drake, MD, PhD, of Columbia University Medical Center, summarizes his keynote lecture on immunotherapy as a new frontier in prostate cancer and its synergistic use with traditional treatments.
Study Finds Cancer Mortality in Hispanics Varies Among Ethnic Groups
Although cancer is a leading cause of death among Hispanics, the burden of cancer mortality within Hispanic groups has not been well quantified. Now, a study by Pinheiro et al comparing the differences among Hispanic populations and cancer incidence has found that cancer mortality varies...
Lawrence H. Einhorn, MD, on Testicular Cancer: The Keynote Lecture
Lawrence H. Einhorn, MD, of the Indiana University Simon Cancer Center, summarizes his keynote lecture on the controversies in management of clinical stage I testicular cancer and the long-term consequences of platinum combination chemotherapy.
Toni K. Choueiri, MD, on Urothelial Cancer: Trial Results From Borealis-2
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on apatorsen plus docetaxel vs docetaxel alone in platinum-resistant metastatic urothelial cancer. (Abstract 289)
Joshua Armenia, PhD, on Prostate Cancer: Recent Discoveries
Joshua Armenia, PhD, of Memorial Sloan Kettering Cancer Center, discusses new information that is changing the understanding of prostate cancer, including the identification of a new subclass, which represents 21% of cases, and the discovery of recurrently mutated cancer pathways not previously...
Brian C. Allen, MD, on Assessing Tumor Response: Standard-of-Care vs Computer-Assisted Evaluation
Brian C. Allen, MD, of Duke University Medical Center, discusses the benefits of using a computerized process that provides step-wise guidance, decreases interpretation time, and reduces errors when measuring tumor response to treatment. (Abstract 432)
Olaparib Meets Primary Endpoint in OlympiAD Trial in BRCA-Mutated Metastatic Breast Cancer
On February 17, positive results were announced from the phase III OlympiAD trial comparing olaparib (Lynparza) tablets to physician’s choice of a standard-of-care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2...
2017 GU Cancers Symposium: Atezolizumab Plus Bevacizumab Shows Potential in Metastatic Renal Cell Carcinoma
Results from the phase II IMmotion150 study that compared atezolizumab (Tecentriq) plus bevacizumab (Avastin) and atezolizumab monotherapy to sunitinib (Sutent) alone in patients with previously untreated, locally advanced or metastatic renal cell carcinoma were presented at the 2017 Genitourinary...
2017 GU Cancers Symposium: Updated Efficacy and Tolerability of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
At the 2017 Genitourinary Cancers Symposium, Powles et al presented updated efficacy and safety data for durvalumab in patients with locally advanced or metastatic urothelial cancer (Abstract 286). Updated results from the phase I/II trial showed an objective response rate of 20.4% in all...
Optimal Time to Assess Response After Chemoradiotherapy in Anal Squamous Cell Carcinoma
In a post hoc analysis of the UK ACT II trial reported in The Lancet Oncology, Glynne-Jones et al found that the best time to assess for complete response to chemoradiotherapy in patients with anal squamous cell carcinoma is at approximately 26 weeks from the start of treatment. In the ACT II...
Variable Transparency of Industry-Sponsored Oncology Financial Assistance Programs
A “secret shopper” study reported by Zafar et al in the Journal of Oncology Practice found that transparency of industry-sponsored oncology patient assistance programs varied among programs. Study Details The study involved accessing pharmaceutical manufacturer–sponsored patient ...
Exploring the Opportunities and Challenges of Seamless Drug Development
The traditional three-phase clinical trial process for testing new drugs does not necessarily make sense when it comes to targeted therapies, according to many experts, including regulators, academic researchers, industry chief executive officers, and patient advocates alike. Instead of three...
Many Cancer Survivors Find Online and Telephone Communication With Health-Care Professionals Beneficial
Researchers from the School of Health Sciences at the University of Surrey, Guildford, United Kingdom, have completed the first-ever systematic review of cancer survivors’ experience of online and telephone telehealth interventions in cancer care, according to a recent study reported by Anna Cox,...
Expert Point of View: Michael Boyer, MD
According to Michael Boyer, MD, a medical oncologist at the Chris O’Brien Lifehouse in Sydney, Australia, the development of testing for programmed cell death ligand 1 (PD-L1) has been complex. Efforts at harmonization have been made, but most laboratories actually use a single...
Three Assays and Several Laboratory-Developed Tests Highly Concordant Across Platforms in PD-L1 Immunohistochemistry Testing for NSCLC
Programmed cell death ligand 1 (PD-L1) expression assessed by immunohistochemistry in formalin-fixed, paraffin-embedded tumor tissues is currently the main predictive biomarker for the benefit of anti–programmed cell death protein 1 (PD-1) and anti–PD-L1 agents in patients with non–small cell lung ...
New Lung Cancer Staging Manual Set to Modify Clinical Practice
A revised tumor classification based on 70,967 evaluable patients with non–small cell lung cancer (NSCLC) and 6,189 patients with small cell lung cancer is now available to lung cancer specialists around the world in the form of the 8th edition of the tumor, node, and metastasis (TNM)...
Expert Point of View: Paul Mitchell, MD
“This is a very important systematic review,” commented invited discussant, Paul Mitchell, MD, Associate Professor at the Olivia Newton-John Cancer and Wellness Centre in Melbourne, Australia. “There are theoretical reasons why programmed cell death ligand 1 (PD-L1) inhibitors might cause less...
Efficacy, Toxicity on a Par for Different Classes of Immune Checkpoint Inhibitors
The two main classes of immune checkpoint inhibitors used to treat non–small cell lung cancer (NSCLC) have essentially the same efficacy and toxicity profiles, according to a systematic review and meta-analysis of 23 trials with a total of 5,899 patients.1 Results showed that about one-fifth of...
Expert Point of View: Leora Horn, MD, MSc
The KEYNOTE-028 results confirm that pembrolizumab (Keytruda) is active in extensive-stage small cell lung cancer (SCLC) and lay to rest safety concerns stemming from the higher risk of paraneoplastic syndromes in this disease, according to invited discussant, Leora Horn, MD, MSc, Clinical...
Durable Responses Reported With Pembrolizumab in Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
The programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) has shown durable antitumor activity in patients with extensive-stage small cell lung cancer (SCLC) that expresses programmed cell death ligand 1 (PD-L1), according to an update of the KEYNOTE-028 trial.1 “Median overall ...
Edward Garon, MD, Receives $3.2 Million NIH Grant to Study Immunotherapy Responses in Lung Cancer
Edward Garon, MD, a member of the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center and Associate Professor of Hematology and Oncology at the David Geffen School of Medicine, has received a 5-year, $3.2 million grant from the National Institutes of Health (NIH) to...
Combination Immunotherapy for Lung Cancer: The Wave of the Future
Increasing experience with immunotherapy for lung cancer in both the lab and the clinic is helping to refine treatment approaches and point the way forward, according to Naiyer Rizvi, MD, Director of both Thoracic Oncology and Immunotherapeutics at Columbia University Medical Center in New York....
Elisabeth Heath, MD, FACP, Appointed Associate Center Director for Translational Sciences at Karmanos
Elisabeth Heath, MD, FACP, of the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has been appointed Associate Center Director for Transitional Sciences, effective immediately. She will report to Gerold Bepler, MD, PhD, President and Chief Executive Officer of...
American Skin Association Names David Norris, MD, President
David Norris, MD, Chairman of the Department of Dermatology at the University of Colorado School of Medicine, has become the new President of the American Skin Association (ASA). Dr. Norris will be taking over for Philip Prioleau, MD, who has held the position since 2014. Prior to Dr. Prioleau’s...
2017 ASH-AMFDP Scholars to Study Basic Insights in Blood Cancer Development
The American Society of Hematology (ASH) announced that Justin Taylor, MD, and Roger Belizaire, MD, PhD, have been selected to participate in the American Society of Hematology–Harold Amos Medical Faculty Development Program (ASH-AMFDP). Designed to increase the number of underrepresented...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in high-grade, aggressive B-cell non-Hodgkin lymphomas (NHLs), including newly diagnosed as well as relapsed or refractory...
FDA Approves Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma
On January 19, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica) for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti–CD20-based therapy. Accelerated approval was granted for this indication based...
New Data on Prognostic Factors, Disease Detection, Drug Toxicities, and Treatment Adherence Presented at SABCS
The San Antonio Breast Cancer Symposium (SABCS) offers state-of-the-art information on all aspects of breast cancer biology, diagnosis, and treatment, drawing an international audience of more than 7,500 physicians, researchers, and other health-care professionals from over 90 countries. Through...
Ongoing Phase III Clinical Trials of Immunotherapy in Advanced Non–Small Cell Lung Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapy in lung cancer. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov. Study Title: A Randomized, Double-Blind, Phase...
Managing Toxicities Associated With Immunotherapy for Lung Cancer
Understanding, anticipating, and managing the toxicities associated with immunotherapies for lung cancer are key to steps to safely using and achieving the most benefit from these new agents, according to Beth Eaby-Sandy, MSN, CRNP, OCN, a nurse practitioner at the University of Pennsylvania’s...
Expert Point of View: Philip Poortmans, MD, PhD
Philip Poortmans, MD, PhD, President-Elect of the European CanCer Organisation (ECCO) and Head of the Radiation Oncology Department at Radboud University Medical Center in Nijmegen, the Netherlands, commented: “This research provides good evidence for the benefits of treating advanced-stage head...
Twice-Daily Radiation Therapy May Reduce Mortality in Head/Neck Cancer
Treating patients with head and neck cancer with hyperfractionated twice-daily radiation therapy combined with chemotherapy may potentially reduce mortality, according to new research presented by Claire Petit, PhD, and colleagues at the 2017 European Cancer Congress (ECCO).1 The study included...
Expert Point of View: Paul Mitchell, MD
“The progression-free and overall survival curves of CheckMate 057 suggest the presence of two patient populations with respect to nivolumab (Opdivo): a relatively sensitive one and a less sensitive, possibly even resistant, one, according to invited discussant Paul Mitchell, MD, Associate...
New Analysis of CheckMate 057: Search Continues for Predictors of Outcome With Nivolumab
Prognostic factors and tumor expression of programmed cell death ligand 1 (PD-L1) predict early mortality among patients with previously treated nonsquamous advanced non–small cell lung cancer (NSCLC) who receive nivolumab instead of docetaxel. But these features are not reliable for excluding...
Expert Point of View: Paul Mitchell, MD
“The KEYNOTE-010 updated survival is looking even more impressive with the benefit of pembrolizumab (Keytruda) over docetaxel. Survival at 2 years with pembrolizumab is more than double that with chemotherapy,” commented invited discussant, Paul Mitchell, MD, Associate Professor at the Olivia...
KEYNOTE-010 Update Shows ‘Striking’ Durability of Second-Line Pembrolizumab in NSCLC
Pembrolizumab’s benefit in previously treated advanced non–small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1) is long lasting, persisting even after therapy ends, suggests an update of the KEYNOTE-010 trial.1 Initial results of the randomized phase II/III trial,...
Expert Point of View: Michael Boyer, MBBS, PhD
“Taken together, ATLANTIC’s findings show that “durvalumab is active in heavily pretreated patients, and its degree of activity is related to programmed cell death ligand 1 (PD-L1) expression,” commented invited discussant, Michael Boyer, MBBS, PhD, Chief Clinical Officer and Conjoint Chair of...
Expert Point of View: Vincent J. Picozzi, MD
Vincent J. Picozzi, MD, a pancreatic cancer specialist at Virginia Mason Hospital in Seattle, commented on the findings by Chan et al presented at the 2017 Gastrointestinal Cancers Symposium. Dr. Picozzi first acknowledged that there is a strong biologic rationale for evaluating cabozantinib...
Cabozantinib Elicits Responses in Neuroendocrine and Carcinoid Tumors
In a phase II study reported at the 2017 Gastrointestinal Cancers Symposium, the tyrosine kinase inhibitor cabozantinib (Cometriq) was evaluated in advanced carcinoid and pancreatic neuroendocrine tumors. Radiographic responses to therapy were observed in both tumor subtypes, and compared to other ...
